先声药业新药研究于Nature旗下期刊发表!诺和诺德、贺普药业肝病领域新进展

医药经济报
May 12, 2025

壹西妥昔单抗βⅢ期临床研究发表于高分期刊近日,先声药业自主研发的结直肠癌靶向EGFR抗体药物西妥昔单抗β注射液(商品名:恩立妥®)的Ⅲ期临床研究结果在Nature旗下期刊《Signal Transduction and Targeted Therapy》(信号转导与靶向治疗,影响因子40.8)正式发表。作为国产2.4类改良型生物新药,西妥昔单抗β通过优化抗体糖基化修饰降低免疫原性,有望有效降低患者...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10